BCR::ABL1
Therapeutic response
Precision oncology relationships for therapeutic response involving this biomarker.
Organizations
Biomarkers
Cancer types
Therapies
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| FDA (4) HC (1) | BCR::ABL1 | Chronic Myeloid Leukemia, BCR-ABL1+ | Asciminib | |
| FDA (2) | ABL1 p.T315I, BCR::ABL1 | Chronic Myeloid Leukemia, BCR-ABL1+ | Asciminib | |
| FDA (2) | CD19 +, not BCR::ABL1 | Acute Lymphoblastic Leukemia | Blinatumomab | |
| FDA (4) HC (2) | BCR::ABL1 | Chronic Myeloid Leukemia, BCR-ABL1+ | Bosutinib | |
| FDA (6) HC (2) | BCR::ABL1 | Chronic Myeloid Leukemia, BCR-ABL1+ | Dasatinib | |
| FDA (4) HC (1) | BCR::ABL1 | Acute Lymphoblastic Leukemia | Dasatinib | |
| FDA (4) HC (2) | BCR::ABL1 | Chronic Myeloid Leukemia, BCR-ABL1+ | Imatinib | |
| FDA (4) HC (2) | BCR::ABL1 | Acute Lymphoblastic Leukemia | Imatinib | |
| FDA (6) HC (4) | BCR::ABL1 | Chronic Myeloid Leukemia, BCR-ABL1+ | Nilotinib | |
| FDA (2) | BCR::ABL1 | Acute Lymphoblastic Leukemia | Cytarabine, Dexamethasone, Methotrexate, Ponatinib, Prednisone, Vincristine | |
| FDA (2) HC (1) | ABL1 p.T315I, BCR::ABL1 | Acute Lymphoblastic Leukemia | Ponatinib | |
| FDA (2) HC (1) | ABL1 p.T315I, BCR::ABL1 | Chronic Myeloid Leukemia, BCR-ABL1+ | Ponatinib |